Galapagos (GLPG) Gets a Hold Rating from RBC Capital


In a report issued on May 8, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG), with a price target of $154.00. The company’s shares closed last Friday at $217.12.

According to TipRanks.com, Abrahams is a 5-star analyst with an average return of 14.0% and a 57.2% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Proteostasis Therapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on Galapagos is a Moderate Buy with an average price target of $230.40.

See today’s analyst top recommended stocks >>

The company has a one-year high of $274.03 and a one-year low of $110.92. Currently, Galapagos has an average volume of 192K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts